{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:07:55Z","timestamp":1793729275549,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1053\/j.ajkd.2022.12.019","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T08:30:26Z","timestamp":1681461026000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Kidney Transplantation From Hepatitis C Virus\u2013Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update"],"prefix":"10.1053","volume":"82","author":[{"given":"Craig E.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelen P.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan M.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ajkd.2022.12.019_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.34067\/KID.0001172020","article-title":"The Advancing American Kidney Health (AAKH) Executive Order: promise and caveats for expanding access to kidney transplantation","volume":"1","author":"Lentine","year":"2020","journal-title":"Kidney360"},{"issue":"6","key":"10.1053\/j.ajkd.2022.12.019_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MNH.0000000000000456","article-title":"Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV","volume":"27","author":"Ruck","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"10.1053\/j.ajkd.2022.12.019_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2022.12.019_bib4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1097\/TP.0000000000002323","article-title":"Changes in utilization and discard of HCV antibody-positive deceased donor\u00a0kidneys in the era of direct-acting antiviral therapy","volume":"102","author":"Bowring","year":"2018","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.ajkd.2022.12.019_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.10960720","article-title":"Trends in discard of kidneys from hepatitis C viremic donors in the United States","volume":"16","author":"Chang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2022.12.019_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2022.12.019_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.ajkd.2022.12.019_bib8","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"issue":"6S","key":"10.1053\/j.ajkd.2022.12.019_bib9","first-page":"S129","article-title":"KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2022.12.019_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1053\/j.ajkd.2022.12.019_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease","volume":"8","year":"2018","journal-title":"Kidney Int Suppl (2011)"},{"issue":"109","key":"10.1053\/j.ajkd.2022.12.019_bib13","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2022.12.019_bib14","series-title":"Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium (IHI \u201912)","first-page":"819","article-title":"Deploying an interactive machine learning system in an evidence-based practice center: abstrackr","author":"Wallace","year":"2012"},{"key":"10.1053\/j.ajkd.2022.12.019_bib15","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2022.12.019_bib16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1053\/j.ajkd.2022.12.019_bib18","first-page":"1","article-title":"OpenMetaAnalyst: closing the gap between methodologists and end-users: R as a computational back-end","volume":"49","author":"Wallace","year":"2012","journal-title":"J\u00a0Stat Softw"},{"issue":"11","key":"10.1053\/j.ajkd.2022.12.019_bib19","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jclinepi.2014.11.023","article-title":"Grading the strength of a body of evidence when assessing health care interventions: an EPC update","volume":"68","author":"Berkman","year":"2015","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"7650","key":"10.1053\/j.ajkd.2022.12.019_bib20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2022.12.019_bib21","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.933313","article-title":"Sofosbuvir\/velpatasvir prophylaxis for 12 weeks in hepatitis C virus (HCV)-negative recipients receiving kidney transplantation from HCV-positive donors","volume":"26","author":"Chen","year":"2021","journal-title":"Ann Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2022.12.019_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001217","article-title":"Kidney transplantation from hepatitis C viremic deceased donors to aviremic recipients in a real-world setting","volume":"7","author":"Concepcion","year":"2021","journal-title":"Transplant Direct"},{"issue":"4","key":"10.1053\/j.ajkd.2022.12.019_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN110487","article-title":"A\u00a0real-world, single-center experience of the utilization of hepatitis C-viremic kidneys for hepatitis C-negative recipients","volume":"96","author":"Daloul","year":"2021","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2022.12.019_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1053\/j.ajkd.2022.12.019_bib25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1053\/j.ajkd.2022.12.019_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients","volume":"20","author":"Gupta","year":"2020","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2022.12.019_bib27","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1111\/ajt.16747","article-title":"Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants","volume":"21","author":"Gupta","year":"2021","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2022.12.019_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13494","article-title":"Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys","volume":"33","author":"Mazur","year":"2019","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2022.12.019_bib29","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1681\/ASN.2020050686","article-title":"Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection","volume":"31","author":"Sise","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2022.12.019_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ekir.2021.11.022","article-title":"One-year outcomes of the Multi-Center Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC) trial","volume":"7","author":"Sise","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2022.12.019_bib31","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/hep.31551","article-title":"Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors","volume":"73","author":"Terrault","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1053\/j.ajkd.2022.12.019_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13833","article-title":"Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access","volume":"34","author":"Graham","year":"2020","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2022.12.019_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14386","article-title":"Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation","volume":"35","author":"Hudson","year":"2021","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2022.12.019_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13540","article-title":"Hepatitis C-positive donor to negative recipient kidney transplantation: a real-world experience","volume":"23","author":"Jandovitz","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2022.12.019_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis c virus-negative recipients: a real-world experience","volume":"72","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1053\/j.ajkd.2022.12.019_bib36","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience","volume":"19","author":"Molnar","year":"2019","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2022.12.019_bib37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2020.10.017","article-title":"Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes","volume":"77","author":"Molnar","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2022.12.019_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13449","article-title":"Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients","volume":"23","author":"Torabi","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2022.12.019_bib39","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2215\/CJN.01850309","article-title":"Interferon for hepatitis C virus in hemodialysis\u2014an individual patient meta-analysis of factors associated with sustained virological response","volume":"4","author":"Gordon","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2022.12.019_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ekir.2022.11.008","article-title":"A\u00a0systematic review of direct-acting antivirals for hepatitis C in advanced CKD","volume":"8","author":"Balk","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2022.12.019_bib41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000495081","article-title":"Trends in the causes of death among kidney transplant recipients in the United States (1996-2014)","volume":"48","author":"Awan","year":"2018","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2022.12.019_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ackd.2016.07.001","article-title":"Current status of kidney transplant outcomes: dying to survive","volume":"23","author":"Wang","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ajkd.2022.12.019_bib43","article-title":"Efficacy and safety of direct-acting antivirals in kidney transplantation from HCV-viremic donors to negative recipients: a meta-analysis","volume":"9","author":"Feng","year":"2022","journal-title":"Front Med (Lausanne)"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623005929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623005929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T05:34:23Z","timestamp":1722058463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638623005929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0272638623005929"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.12.019","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Transplantation From Hepatitis C Virus\u2013Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}